Research
Pushing Boundaries Through In-house Science
Abmining
Massive antibody mining, an unique platform for accelerating R&D timeline of therapeutic antibodies. Proprietary Topo-Antibody® with global epitope coverage combines with digital immortalization facilitate accelerated timeline for the development of new antibody therapeutics. If you are interested in Abmining project, please feel free to contact us for further discussion!
Learn more
PD-L1 Decoy
Development of a high-affinity PD-L1 decoy protein as a therapeutic molecule. Programmed cell death protein-1 (PD-1) and its ligand (PD-L1) are immune checkpoint proteins that inform the response of cytotoxic T lymphocytes (CTLs) that have recognized tumor cell antigen presentation on major histocompatibility complexes (MHCs) via T cell receptors (TCRs). Successful signaling between PD-1 and PD-L1 suppresses the anti-tumor immune response of CTLs, allowing tumor cells to proliferate. Blockade of PD-1/PD-L1 signaling is therefore a promising cancer treatment strategy. Our goal is to engineer an oligomeric decoy with enhanced binding affinity (avidity) to PD-L1 such that it can effectively result in blockade and confer a therapeutic benefit. If you are interested in PD-L1 Decoy project, please feel free to contact us for further discussion!
Learn more
PRIM
Recombinant protein as a Pan Receptor Interacting Molecule PRIM molecules are recombinant oligomeric Fc human protein and are capable of interacting with all human Fcγ receptors with high avidity. PRIM proteins are highly efficacious in autoimmune animal models and are developmental candidates for replacing the traditional plasma-derived human IVIG. If you are interested in PRIM project, please feel free to contact us for further discussion!
Learn more